Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PROSCA BLADDR 2021 | Germline testing in urothelial cancer

Petros Grivas, MD, PhD, Seattle Cancer Care Alliance, Seattle, WA, touches on the role of genomic testing in patients with urothelial cancer, highlighting the importance of identifying targetable mutations. In addition, Dr Grivas reports the high incidence of somatic alterations seen in urothelial carcinoma which have implications for patients as well as their families. This interview took place at the PROSCA/BLADDR 2021 congress.